Maccura Biotechnology (300463.SZ) forecasts a decrease in annual net profit to be between 120 million yuan and 180 million yuan, a year-on-year decline of 42.42% to 61.61%.
Mike Bio (300463.SZ) disclosed its performance forecast for the year 2024. The company expects that the net profit attributable to shareholders of the listed company...
Maccura Biotechnology (300463.SZ) disclosed the performance forecast for 2024, with the company expecting a net profit attributable to shareholders of the listed company of 120 million to 180 million yuan, a year-on-year decrease of 42.42% to 61.61%; the net profit after deducting non-recurring gains and losses is expected to be 118 million to 177 million yuan, a year-on-year decrease of 43.93% to 62.62%.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
